» Articles » PMID: 38195844

Uncovering Hidden Cancer Self-dependencies Through Analysis of ShRNA-level Dependency Scores

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jan 10
PMID 38195844
Authors
Affiliations
Soon will be listed here.
Abstract

Large-scale short hairpin RNA (shRNA) screens on well-characterized human cancer cell lines have been widely used to identify novel cancer dependencies. However, the off-target effects of shRNA reagents pose a significant challenge in the analysis of these screens. To mitigate these off-target effects, various approaches have been proposed that aggregate different shRNA viability scores targeting a gene into a single gene-level viability score. Most computational methods for discovering cancer dependencies rely on these gene-level scores. In this paper, we propose a computational method, named NBDep, to find cancer self-dependencies by directly analyzing shRNA-level dependency scores instead of gene-level scores. The NBDep algorithm begins by removing known batch effects of the shRNAs and selecting a subset of concordant shRNAs for each gene. It then uses negative binomial random effects models to statistically assess the dependency between genetic alterations and the viabilities of cell lines by incorporating all shRNA dependency scores of each gene into the model. We applied NBDep to the shRNA dependency scores available at Project DRIVE, which covers 26 different types of cancer. The proposed method identified more well-known and putative cancer genes compared to alternative gene-level approaches in pan-cancer and cancer-specific analyses. Additionally, we demonstrated that NBDep controls type-I error and outperforms statistical tests based on gene-level scores in simulation studies.

Citing Articles

Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.

Karimpour M, Totonchi M, Behmanesh M, Montazeri H Life Sci Alliance. 2023; 7(1).

PMID: 37863651 PMC: 10589366. DOI: 10.26508/lsa.202302268.

References
1.
Sundara Rajan S, Ludwig K, Hall K, Jones T, Caplen N . Cancer biology functional genomics: From small RNAs to big dreams. Mol Carcinog. 2020; 59(12):1343-1361. PMC: 7702050. DOI: 10.1002/mc.23260. View

2.
Dai M, Yan G, Wang N, Daliah G, Edick A, Poulet S . In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy. Nat Commun. 2021; 12(1):3055. PMC: 8144221. DOI: 10.1038/s41467-021-23316-4. View

3.
Arfaoui A, Rioualen C, Azzoni V, Pinna G, Finetti P, Wicinski J . A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Mol Med. 2019; 11(10):e9930. PMC: 6783652. DOI: 10.15252/emmm.201809930. View

4.
Shao D, Tsherniak A, Gopal S, Weir B, Tamayo P, Stransky N . ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 2012; 23(4):665-78. PMC: 3613583. DOI: 10.1101/gr.143586.112. View

5.
Schmich F, Szczurek E, Kreibich S, Dilling S, Andritschke D, Casanova A . gespeR: a statistical model for deconvoluting off-target-confounded RNA interference screens. Genome Biol. 2015; 16:220. PMC: 4597449. DOI: 10.1186/s13059-015-0783-1. View